Levatol

Quick links to important sections

Levatol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levatol

Property Description
Active ingredient Penbutolol sulfate
Form Tablet (Oral administration)
Pharmacological class Beta-adrenergic receptor antagonist (Beta-blocker)
General use Management of high blood pressure (Arterial hypertension)
Origin Synthetic compound

What is Levatol and its Active Ingredient?

Levatol is a prescription medication whose active ingredient is penbutolol sulfate, a single-ingredient, synthetic compound derived from the ethanolamine structure. It is manufactured for oral administration as a solid tablet. Levatol is a brand name that contained penbutolol sulfate, which defines its identity as a small molecule drug intended to affect cardiovascular function.

Levatol's Classification as a Non-Selective Beta-Blocker

Penbutolol is categorized as a beta-adrenergic receptor antagonist, widely known as a beta-blocker. This agent is specifically non-selective, influencing both the beta-1 receptors of the heart and the beta-2 receptors in the bronchial and vascular tissues. A distinctive feature that sets penbutolol apart within its class is its Intrinsic Sympathomimetic Activity (ISA). This property is chemically inherent to the penbutolol molecule and has been pharmacologically characterized to provide a minimal internal stimulatory effect on beta receptors while simultaneously blocking the full impact of stress hormones.

General Purpose and Physiological Role of Penbutolol

The drug’s fundamental physiological role is to reduce the workload on the heart and to slow its rate of contraction. This mechanism, which modulates the cardiovascular response to sympathetic nerve impulses, is primarily employed for the management of arterial hypertension (high blood pressure). For instance, it is typically used in a scenario where a patient requires sustained maintenance therapy to achieve and maintain a reduced, steady circulatory pressure fulfilling its overarching purpose of providing hemodynamic stability.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Levatol?

Possible side effects and safety information

The safety profile of Levatol (penbutolol sulfate) is officially documented by government regulatory bodies, detailing adverse reactions by frequency and physiological system. Common reactions, reported in 1.5% or more of patients during clinical trials, are frequently related to the Nervous System and Gastrointestinal Disorders.


Documented Adverse Reactions and Frequency

Adverse effects listed as Common include headache, dizziness, fatigue, nausea, and diarrhea. Less frequent reactions classified as Uncommon/Less Frequent include insomnia, asthenia, and sexual impotence. The incidence of fatigue, nausea, and sexual impotence has been noted to increase as the administered dose is escalated.


Serious Safety Constraints

Official labeling defines several serious constraints and contraindications. The drug is contraindicated in conditions such as cardiogenic shock, sinus bradycardia, advanced atrioventricular (AV) conduction block, and bronchial asthma. Use requires caution in patients with a history of cardiac failure, as the medication may worsen the condition.

A specific safety pattern is linked to cessation: Abrupt withdrawal can lead to an exacerbation of angina symptoms or, in some cases, precipitate a myocardial infarction.

Population-Specific Safety Notes

The medication may mask the clinical signs of underlying metabolic conditions, specifically hypoglycemia in patients with diabetes or certain symptoms of hyperthyroidism. Caution is advised when used in older adults and those with kidney disease, as dose adjustments may be necessary due to slower clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose with Levatol (penbutolol) is characterized by an extreme exaggeration of its pharmacological effects, primarily leading to severe cardiovascular depression. Official regulatory guidance mandates that individuals seek immediate medical attention for all suspected cases. It is required to contact a poison control center or emergency room at once.

The officially documented clinical profile highlights effects on the heart, blood pressure, and central nervous system. Treatment for overdose is strictly symptomatic and supportive, as regulatory documents state that no specific antidote is known for penbutolol.

Documented Overdose Profile Regulator-Identified Manifestations and Actions
Primary Manifestations Bradycardia (slow heart rate), severe hypotension, acute heart failure, and atrioventricular block (AV block).
Severe Outcomes Potential for progression to cardiogenic shock, severe respiratory depression, and profound neurological effects.
Emergency Management Administration of atropine or intravenous glucagon for refractory cardiovascular effects. Continuous cardiac monitoring is required for observation.
Special Consideration Patients undergoing renal dialysis are noted to have an increased risk of severe exposure dueences to the delayed clearance of a drug metabolite.

Therapeutic Uses of Levatol

What Levatol Treats: Main Uses and Benefits

Levatol (penbutolol) is commonly used to provide sustained support for the cardiovascular system, primarily by managing persistently elevated blood pressure. It is indicated for the treatment of mild to moderate arterial hypertension.


Management of Chronic Arterial Hypertension

the medication is applied in conditions characterized by chronic, elevated systolic and diastolic pressure. Levatol is relevant for easing this fundamental pressure manifestation, which creates noticeable physiological strain on the circulatory system. It is relevant for managing symptoms related to systemic imbalance, making it applicable in conditions involving heightened systemic burden. The primary therapeutic use is helping manage arterial hypertension, commonly known as high blood pressure.

“This medication is used to provide support that helps ease the overall symptom burden by moderating the physiological strain associated with chronically high blood pressure.”


Support for Hemodynamic Stability and Regimens

This medication is relevant when supportive symptom management is appropriate, as it is often used during phases when symptoms of hypertension could lead to long-term functional stress. In clinical scenarios, Levatol is commonly used to help with the therapeutic management of high blood pressure, frequently applied in combination with other agents, such as thiazide-type diuretics. This approach contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Blood Pressure Imbalance
Used for managing: Elevated Vascular Pressure Patterns and associated Heightened Systemic Burden.
Main benefit: Contributes to improved comfort by maintaining functional stability and easing distress associated with chronic high blood pressure.

Eligibility and Restrictions for Use

Levatol (penbutolol sulfate) eligibility is defined by official regulatory documents, strictly specifying populations permitted for use and those who are absolutely prohibited. The medication is indicated for the treatment of mild to moderate arterial hypertension in adults.


Absolute Contraindications (Must Not Use)

Official labeling strictly prohibits the use of Levatol in patients with pre-existing severe conditions, including:

  • Cardiogenic Shock
  • Sinus Bradycardia
  • Second or Third-Degree Atrioventricular Conduction Block
  • Bronchial Asthma
  • Known Hypersensitivity to penbutolol sulfate

Restricted or Non-Established Use

Use requires caution or is not supported by data in the following specific groups, as documented in official labeling:

Population / Condition Regulatory Status
Pediatric Population Safety and efficacy have not been established.
Pregnancy / Lactation Use is restricted; safety is not established.
Compensated Cardiac Failure Use with caution; overt heart failure must be avoided.
Renal Impairment Use with caution; potential for slower drug clearance.
Diabetes / Hyperthyroidism Use with caution due to the masking of symptoms.

Eligibility is conditional upon the absence of absolute contraindications and the application of required caution for specific comorbidities and demographics, such as the Geriatric Population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Levatol (penbutolol sulfate) describes documented effects primarily related to pharmacodynamic reinforcement and specific clearance constraints, according to official regulatory information.

Documented Interaction Patterns

Interacting Substance/Condition Regulatory Description of Interaction
Digitalis compounds (e.g., Digoxin) Co-administration results in an additive effect of slowing AV conduction (atrioventricular conduction).
Hypoglycemic Agents Beta-adrenergic blockade may mask certain signs of acute hypoglycemia, such as tachycardia.
Alcohol (Ethanol) Co-administration increased the number of errors observed in the eye-hand psychomotor function test.
Hydrochlorothiazide Used in combination in clinical studies without unexpected adverse reactions, documenting a co-administration pattern.
Renal Insufficiency Accumulation of the penbutolol conjugate is expected upon multiple-dosing due to altered renal clearance (Population-Specific PK).

The official labeling notes that Clonidine and Epinephrine are classified as clinically important interactions in government-derived formularies. The FDA prescribing information for Levatol does not formally list any drug-drug combination as contraindicated, nor does it mandate specific timing separation rules for administration. The overall structure is defined by the additive cardiac and metabolic effects resulting from co-administration.

Mechanism of Action

Levatol (penbutolol) functions as a non-selective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity (partial agonist). Its primary molecular targets are the beta1 and beta2 adrenergic receptors, which are G-protein coupled receptors.

At the cardiac beta1 receptors, Levatol competitively blocks the binding of endogenous catecholamines, such as norepinephrine. This antagonism attenuates the activation of adenylyl cyclase, thereby decreasing the intracellular concentration of cyclic AMP (cAMP) and subsequent protein kinase A (PKA) activity. The net intracellular consequence is a reduction in calcium ion flux, leading to decreased myocardial contractility and heart rate.

In the juxtaglomerular apparatus of the kidney, beta1 receptor antagonism inhibits the release of renin. This action modulates the renin-angiotensin-aldosterone system by suppressing the downstream production of angiotensin II and aldosterone. The system-level physiological consequence of these combined actions—reduced cardiac output and diminished renin activity—is the modulation of systemic blood pressure.

Dosage and Administration Information

How Levatol (Penbutolol Sulfate) is Used

Standard usage protocols for Levatol detail the administration route, standard adult dosing, frequency, and specific requirements for chronic use.

Official Administration and Dosage

Levatol is prescribed for oral administration as a tablet for the long-term management of high blood pressure.

Usage Aspect Official Instruction (Adults)
Route of Administration Oral
Initial Daily Dose 20 mg once daily
Maintenance Dose Range 20 mg to 40 mg daily
Dosing Frequency Typically once daily, although the maintenance dose may be divided into two equally administered doses

Administration Context and Adjustments

The tablet can be taken with or without food. For patients with hepatic impairment, the starting dose is generally recommended to be lower, at 10 mg once daily, and subsequent adjustments must be made cautiously. No specific dosing instructions are provided in the labeling for patients with impaired renal function, and the medicine is not established for use in pediatric patients under 18 years of age.

Procedural Note on Cessation

Levatol is intended for chronic administration. The full therapeutic effect of a dose may take four to six weeks of consistent use to become fully apparent. If the medication is to be stopped, the dose must be gradually reduced over a period of time to avoid certain procedural risks, such as acute hypertension. If a dose is missed, it should be taken as soon as possible, but double doses must not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes what was evaluated in clinical research related to the compound. It is based solely on the scientific literature and should not be interpreted as advice or a recommendation.

Key Efficacy Findings

Research has explored whether this compound may affect the duration and severity of cold symptoms.

  • Symptom Duration: Clinical trials evaluated whether an effect on the overall length of cold symptoms was observed. Studies examined whether a reduction in the duration of symptoms was observed in adult participants.
  • Symptom Severity: Research investigated the compound's possible effect on self-reported measures of symptom intensity (e.g., congestion, sore throat, cough).
  • Fever Management: Studies have evaluated whether a reduction in fever is observed over a 24-hour period following administration.

Mechanism of Action (How it was Studied)

This compound is reported to act as a COX-2 enzyme inhibitor. Studies have investigated the relationship between this mechanism and observations related to pain and swelling.

Comparative Studies

  • Comparison to Placebo: A central focus of the research was comparing outcomes in groups receiving the compound versus groups receiving an inactive placebo. Studies have examined patient-reported outcomes, duration of illness, and incidence of adverse events in these comparisons.
  • Comparison to Standard Care: Studies have examined whether patient outcomes differ when compared to standard care treatments.
  • Comparison to Older Formulations: Research has compared this formulation with older treatments to evaluate observations related to symptoms and tolerability.

Use in Specific Populations

  • Pediatric Use (Ages 6–12): Research evaluated the effects of a lower dose of the compound in children aged 6 to 12. Initial studies investigated tolerability in this population.
  • Pregnant Women: Some research has investigated the compound's use in pregnant women; however, evidence remains limited. The research focused primarily on potential short-term adverse effects.

Investigational Combination Therapies

Studies have examined the use of the compound in combination with Drug X for the management of chronic migraines. Research explored the safety profile and observations related to headache frequency and intensity when these two compounds were used together.

Key Studies & References

  1. COX Inhibitors: Mechanism of Action and Clinical Application (Systematic review on COX-2 inhibition)
  2. Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation (Source for context on pediatric studies, Ages 6-12)

Frequently Asked Questions (FAQ)

Common questions about Levatol (FAQ)


Q: Can Levatol lead to weight gain?

Official medical information notes that rapid weight gain is a symptom that has been associated with this class of medication or the underlying condition it treats. This is listed as a change that may be monitored during treatment.


Q: How quickly does Levatol begin to work after the first dose?

Studies indicate the medicine begins to work on heart function shortly after the first dose, with observed changes in the reduction of exercise-induced heart rate lasting for at least 24 hours. However, the full, steady blood pressure-lowering effect may take several weeks of consistent use to develop.


Q: Are there any common foods or drinks that should be avoided with Levatol?

Official product labeling advises that the tablet can be taken with or without food. The primary substance noted for an interaction is alcohol, which has been shown in studies to increase errors in psychomotor function tests when co-administered with this medication.


Q: Does Levatol interact with over-the-counter pain relievers like ibuprofen?

The core regulatory information does not explicitly list non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen as a known interaction. However, official documentation generally advises that all nonprescription medicines be discussed with a healthcare provider.


Q: Can herbal or vitamin supplements affect how Levatol works?

Official documentation indicates that it is important to disclose all substances to a healthcare provider. This includes prescription and nonprescription medications, along with any vitamins, nutritional supplements, and herbal products, as they may affect the drug’s activity.


Q: Is Levatol the same as other 'lol' medicines, or how is it different?

Levatol belongs to the class of medicines commonly known as beta-blockers. It has a distinguishing characteristic called Intrinsic Sympathomimetic Activity (ISA). This means that while it blocks the full effect of stress hormones, it also provides a minimal level of internal stimulation to the beta-receptors, setting it apart from beta-blockers without ISA.


Q: Are there different brand names or a generic version of Levatol available?

Levatol is a brand name, and its active ingredient is penbutolol sulfate. The compound is available as a generic oral tablet form under the chemical name penbutolol sulfate.


Q: How does Levatol differ from a calcium channel blocker?

Levatol is classified as a beta-blocker, which works primarily by blocking specific receptors for stress hormones on the heart. In contrast, Calcium Channel Blockers (CCBs) are a different class of drug that works by interfering with the movement of calcium into heart and blood vessel cells.


Q: What is the research evidence for Levatol in treating heart failure?

Official warnings indicate that Levatol is contraindicated (must not be used) in patients who have overt cardiac failure. For other patients, the regulatory documents contain warnings that the continued use of beta-blocking agents may, in some cases, lead to the development of cardiac failure.


Q: Can Levatol affect mood or cause depressive symptoms?

Official drug information lists depression as an adverse reaction reported with the use of this medicine or other agents in the same drug class. Other mental status changes are also noted in the safety profile.


Q: What type of monitoring (like blood tests) is often needed when taking Levatol?

According to general drug guidance, regular monitoring is often necessary when taking this medication. This typically involves checking your blood pressure and tracking your pulse or heart rate. The frequency and exact method of monitoring are determined on an individualized basis.


Q: What official information is available about Levatol's long-term safety?

Official regulatory warnings address long-term considerations by noting that the sustained reduction of heart function, or depression of the myocardium, could potentially lead to the development of cardiac failure in some individuals, even if they had no prior history of the condition.


Q: Does Levatol have any known interaction with popular cold and flu medicines?

Many popular cold and flu medicines contain ingredients, such as sympathomimetic agents, that are known to elevate blood pressure and heart rate. Because Levatol works to lower these values, a potential conflict in action may occur.


Q: Is Levatol described in official sources as affecting blood sugar levels?

Official documents state that this medication has been noted to potentially cause both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar). Furthermore, in individuals with diabetes, it may make the usual symptoms of low blood sugar harder to recognize.


Q: Does Levatol change how other medications are absorbed in the body?

Regulatory information emphasizes changes in drug activity (pharmacodynamics) and how the body breaks down and removes the drug (clearance). While the official labeling does not specifically detail changes in the absorption rate of other medicines, general guidance may advise separating the administration of certain concurrent drugs.


Q: Can Levatol affect a person's ability to drive or operate machinery?

Side effects reported with Levatol include dizziness and feelings of somnolence or fatigue. For this reason, official guidance suggests that individuals assess their reaction to the medication before attempting to drive, operate complex machinery, or participate in activities requiring full attention.


Q: What are the known severe or rare side effects associated with Levatol?

The official safety profile notes several serious constraints, including a warning that abrupt withdrawal can lead to worsened chest pain (angina) or a heart attack (myocardial infarction). The drug is also contraindicated in patients with severe pre-existing conditions like cardiogenic shock and bronchial asthma.


Q: How does the use of Levatol change for older adults compared to younger people?

Regulatory information specifically advises the use of caution when the drug is administered to older adults. This is because the body may clear the medication more slowly, potentially resulting in the need for dose adjustments to maintain appropriate therapeutic levels.

How should Levatol be stored and disposed of?

Levatol (penbutolol sulfate) must be stored strictly according to regulatory specifications to preserve product quality.

Storage Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) [Source 2.1].
Protection Keep from freezing and protect from excess heat and moisture [Source 2.1].
Container Rule Keep in the original container and maintain it tightly closed [Source 2.1].

  • Child Safety: The tablets must be stored securely out of reach of children [Source 2.1].
  • Disposal: Unused or expired medication should be discarded via a drug take-back program. If a take-back option is unavailable, the official method is to mix the tablets with an undesirable substance (such as used coffee grounds or dirt), place the mixture in a sealed container, and dispose of it in the household trash. Do not flush Levatol down the toilet [Source 1.6, Source 1.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levatol found in:

A-Z Index: